ArticleLeukemia research2017
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.
Open access · greenAbstract read
In one paragraph
Article in Leukemia research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.Blood advances · 2020Trial
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.JAMA oncology · 2018Trial
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.The Lancet. Haematology · 2017Trial
- Fedratinib in 2025 and beyond: indications and future applications.Blood advances · 2025Review
- Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST-2 Landmark Analysis of Survival.European journal of haematology · 2025Article
- Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) in Chronic Myeloproliferative Neoplasms with Relation to Genetic Burden and ThrombosisTurkish journal of haematology : official journal of Turkish Society of Haematology · 2024Article
- Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials.HemaSphere · 2023Article
- Article
- Physician Perceptions of the Clinical, Economic and Humanistic Burden of Disease and Unmet Needs in Myelofibrosis: Preliminary Findings from the MPN Landmark Survey in Indonesia.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis.Haematologica · 2023Article
- Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments.Cancers · 2023Review
- Long-Term Hematologic Improvement in a Patient With Cytopenic Myelofibrosis Treated With Pacritinib.JCO precision oncology · 2023Article
- Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.Haematologica · 2022Article
- Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported.Leukemia research · 2020Article
- Integrative Approaches to Managing Myeloproliferative Neoplasms: the Role of Nutrition, Exercise, and Psychological Interventions.Current hematologic malignancy reports · 2019Review
- Approach to MPN Symptom Assessment.Current hematologic malignancy reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
52 authors at 20 institutions in 13 countries.
Allison H ScotchDepartment of Internal Medicine, Mayo Clinic, Scottsdale, AZ USA. Electronic address: allison.scotch@gmail.com.
Heidi KosiorekSection of Biostatistics, Mayo Clinic, Scottsdale, AZ USA.
Robyn ScherberOregon Health and Sciences University, Portland, OR USA.
Amylou C DueckSection of Biostatistics, Mayo Clinic, Scottsdale, AZ USA.
Stefanie SlotDepartment of Hematology, VU University Medical Center, Amsterdam, Netherlands.
Sonja ZweegmanDepartment of Hematology, VU University Medical Center, Amsterdam, Netherlands.
Peter A W Te BoekhorstDepartment of Hematology, Erasmus MC, Rotterdam, Netherlands.
Suzan CommandeurDepartment of Dermatology, LUMC, Leiden, Netherlands.
Harry SchoutenDepartment of Hematology, MUMC, Maastricht, Netherlands.
Federico SackmannFundaleu, Buenos Aires, Argentina.
Ana Kerguelen FuentesDepartment of Haematology, University Hospital La Paz, Madrid, Spain.
Dolores Hernández-MaraverDepartment of Haematology, University Hospital La Paz, Madrid, Spain.
Heike L PahlDepartment of Molecular Hematology, University Hospital Freiburg, Freiburg, Germany.
Martin GriesshammerJohannes Wesling Klinikum Minden, Germany.
Frank StegelmannDepartment of Internal Medicine III, University Hospital of Ulm, Germany.
Konstanze DöhnerDepartment of Internal Medicine III, University Hospital of Ulm, Germany.
Thomas LehmannHematology Department, University Hospital Basel, Switzerland.
Karin BonatzMedizinische Klinik, Universitätsmedizin Mannheim, Germany.
Andreas ReiterMedizinische Klinik, Universitätsmedizin Mannheim, Germany.
Francoise BoyerCentre Hospitalier Universitaire, Angers, France.
Gabriel EtienneInstitut Bergonie, Bordeaux, France.
Jean-Christophe IanottoCentre Hospitalier Universitaire, Brest, France.
Dana RantaHospitalier Universitaire, Nancy, France.
Lydia RoyCentre Hospitalier Universitaire, Poitiers, France.
Jean-Yves CahnCentre Hospitalier Universitaire, Grenoble, France.
Claire N HarrisonDept of Haematology, Guy's and St. Thomas NHS Foundation Trust, London, United Kingdom.
Deepti RadiaDept of Haematology, Guy's and St. Thomas NHS Foundation Trust, London, United Kingdom.
Pablo MuxiUnidadde Hematología, Hospital Británico, Montevideo, Uruguay.
Norman MaldonadoUniversity of Puerto Rico School of Medicine, San Juan, Puerto Rico.
Carlos BessesHematology Department, Hospital del Mar, Barcelona, Spain.
Francisco CervantesHematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Spain.
Peter L JohanssonInternal Medicine, NU Hospital Organization, Uddevalla, Sweden.
Tiziano BarbuiUnit of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy.
Giovanni BarosiLab of Clinical Epidemiology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Alessandro M VannucchiHematology, Dept of Medical and Surgical Care, University of Florence, Florence, Italy.
Chiara PaoliHematology, Dept of Medical and Surgical Care, University of Florence, Florence, Italy.
Francesco PassamontiDepartment of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
Bjorn AndreassonInternal Medicine, NU Hospital Organization, Uddevalla, Sweden.
Maria L FerrariBiol Sci., Ospedali Riuniti di Bergamo, Bergamo, Italy.
Alessandro RambaldiUnit of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy.
Jan SamuelssonDepartment of Internal Medicine, Stockholm South Hospital, Stockholm, Sweden.
Gunnar BirgegardDept of Hematology, University Hospital, Uppsala, Sweden.
Zhijian XiaoMDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Zefeng XuMDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Yue ZhangMDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Xiujuan SunMDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Junqing XuMDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Jean-Jacques KiladjianClinical Investigation Center, Hopital Saint-Louis, Paris, France.
Peihong ZhangDepartment of Pathology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Robert Peter GaleImperial College, London, UK.
Ruben A MesaDepartment of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ USA.
Holly L GeyerDepartment of Internal Medicine, Mayo Clinic, Scottsdale, AZ USA. Electronic address: geyer.holly@mayo.edu.
Mayo Clinic in Arizona · USChinese Academy of Medical Sciences & Peking Union Medical College · CNInstitute of Hematology & Blood Diseases Hospital · CNUniversity of Bergamo · ITAmsterdam UMC Location VUmc · NLHospital Universitario La Paz · ESNU Hospital Group · SEUniversity Hospital Ulm · DECentre Hospitalier Régional et Universitaire de Nancy · FRCentre Hospitalier Régional Universitaire de Brest · FRCentre Hospitalier Universitaire d'Angers · FRCentre Hospitalier Universitaire de Grenoble · FRCentre Hospitalier Universitaire de Poitiers · FRErasmus MC · NLFundación para la Investigación, Docencia y Prevención del Cáncer · ARHeidelberg University · DEHôpital Saint-Louis · FRHospital Británico · UYHospital Del Mar · ESImperial College London · GB
Funding
TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1MNCI NIH HHS P30 CA054174
Abstract
Myelofibrosis is a myeloproliferative neoplasm associated with progressive cytopenias and high symptom burden. MF patients with thrombocytopenia have poor prognosis but the presence of thrombocytopenia frequently precludes the use of JAK2 inhibitors. In this study, we assessed quality of life and symptom burden in 418 MF patients with (n=89) and without (n=329) thrombocytopenia using prospective data from the MPN-QOL study group database, including the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) and Total Symptom Score (MPN10). Thrombocytopenia, defined as platelet count <100×10
Indexed as
Needs AssessmentSeverity of Illness IndexSymptom AssessmentFemaleFollow-Up StudiesHumansMaleMiddle AgedPrimary MyelofibrosisPrognosisProspective StudiesQuality of LifeSurveys and QuestionnairesThrombocytopeniaMyelofibrosisMyeloproliferative neoplasmQuality of lifeSymptomatologyThrombocytopenia
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.